Research programme: botulinum toxins - Ipsen Bioinnovation

Drug Profile

Research programme: botulinum toxins - Ipsen Bioinnovation

Alternative Names: botulinum neurotoxins; SXN

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syntaxin
  • Developer Ipsen Bioinnovation
  • Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Recombinant proteins
  • Mechanism of Action Acetylcholine inhibitors; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 15 Dec 2016 Preclinical development is ongoing United Kingdom (Ipsen pipeline, December 2016)
  • 16 Jul 2016 No recent reports of development identified for research development in Undefined in United Kingdom
  • 15 Jul 2013 Ipsen acquires Syntaxin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top